You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
神威藥業(02877.HK)急挫20%創逾七個月低 董事會認爲現行股息政策需修改
阿思達克 12-28 15:13
神威藥業(02877.HK)早前指集團已完成對一家內地子公司進行增資,涉及金額約7,800萬美元,上述增資將會影響集團可分派的利潤,而董事會認爲現行股息政策需修改。神威藥業今天曾急挫24.6%曾低見5.55元創逾七個月低,現報5.87元,急挫20%,成交急增至637萬股,已創逾五個月高。 摩根士丹利發表報告指,神威藥業公佈新的派息政策,料此對公司短期股價構成波動的影響,維持對神威藥業「與大市同步」投資評級及目標價8.8元。 神威上週四公佈,收入及能否派付股息取決於((其中包括)來自附屬公司的股息,而來自附屬公司的股息又取決於該等附屬公司的可分派溢利、經營業績、財務狀況、資本支出計劃及其他包括但不限於經營所在地的宏觀及微觀因素。因應內地最新的經營情況,集團已完成對一家內地子公司進行增資,涉及金額約7,800萬美元。上述增資將會影響集團可分派的利潤,日後也可能根據實際需要進行類似的事項。因此董事會在檢討現行股息政策後,認爲需要對現行股息政策作出修改,希望通過這次修改,增加靈活性以配合將來內地經營所需,改善集團之資金運用,並滿足公司的整體利益。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account